Cargando…
Compassionate use of recombinant human IL‐7‐hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma
PURPOSE: Addressing lymphopenia in cancer patients has been suggested as a novel immunotherapeutic strategy. As interleukin‐7 (IL‐7) is necessary for proliferation of lymphocytes and to increase total lymphocyte count (TLC), IL‐7 therapy has been attempted in various cancers. Here, we describe the c...
Autores principales: | Ahn, Stephen, Park, Jae‐Sung, Kim, Heewon, Heo, Minkyu, Sung, Young Chul, Jeun, Sin‐Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067043/ https://www.ncbi.nlm.nih.gov/pubmed/36583472 http://dx.doi.org/10.1002/cam4.5467 |
Ejemplares similares
-
hIL‐7‐hyFc, A Long‐Acting IL‐7, Increased Absolute Lymphocyte Count in Healthy Subjects
por: Lee, Sang Won, et al.
Publicado: (2020) -
A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions
por: Kim, Sojeong, et al.
Publicado: (2022) -
Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
por: O’Neal, Julie, et al.
Publicado: (2023) -
A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
por: Kim, Miriam Y., et al.
Publicado: (2022) -
Effect of Cumulative Dexamethasone Dose during Concomitant Chemoradiation on Lymphopenia in Patients with Newly Diagnosed Glioblastoma
por: Lee, Changik, et al.
Publicado: (2020)